MedTrace Logo

Evaluation of The Effect of Virtual Reality Glasses

NCT06474780 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 900

Last updated 2024-06-26

No results posted yet for this study

Summary

The study was planned as a randomized controlled study to evaluate the effect of virtual reality glasses used on anxiety and treatment compliance in outpatient cancer patients receiving chemotherapy. The sample of the study consisted of a total of 30 patients, including 15 experimental and 15 control groups, who received intravenous chemotherapy treatment every 21 days between April 1 and September 31, 2023, in the outpatient chemotherapy unit of a research hospital. Research data will be collected using the Patient Information Form, Beck Anxiety Scale (BAI) and Chronic Disease Adaptation Scale (CCDS). In evaluating the data, it was planned to analyze the differences between the rates of categorical variables in independent groups with Chi-Square tests. It was planned to use t tests to compare quantitative continuous data between two independent groups. Dependent groups t-test will be used to compare measurements within groups. After being informed about the research, patients in both groups will be given a pre-test. Patients in the experimental group will be shown 3 different videos with virtual reality glasses during 3 cycles of chemotherapy treatment, and a final test will be administered to both groups at the end of the 3rd cycle..

Conditions

  • Anxiety
  • Cancer
  • Chemotherapy
  • Virtual Reality
  • Treatment Compliance

Interventions

DEVICE

Weight: 414g Size: 19.5cm x 14cm x 11cm Compatibility: Android and iOS VR Box 3.0 3D Virtual Reality Glasses Has the Feature of Fixation with Headband It has a lens mechanism tha

Patients in the experimental group were fitted with virtual reality glasses for 3 cycles and were allowed to watch videos of city tours, walks in the forest, and nature walks for 15 minutes, depending on their choice.

Sponsors & Collaborators

  • Gozde Oz

    lead OTHER

Eligibility

Min Age
42 Years
Max Age
62 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-28
Primary Completion
2024-06-30
Completion
2024-08-25

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06474780 on ClinicalTrials.gov